低剂量帕博利珠单抗联合新辅助化疗治疗局部三阴性乳腺癌的II期随机研究
这项在印度新德里开展的II期随机开放标签研究,纳入157例既往未治疗的II-III期TNBC患者,1:1随机接受低剂量帕博利珠单抗(50 mg每6周共3次)联合剂量密集新辅助化疗或单纯化疗。意向治疗人群中,联合组病理完全缓解率为53.8%,对照组为40.5%,绝对差异13.3%(90%CI 0.3%-26.3%,单侧P=0.047)。
要点
- 低剂量帕博利珠单抗联合新辅助化疗较单纯化疗显著提高pCR率。
- 联合组与对照组≥3级毒性发生率分别为50%和59.5%。
- 在无法获得标准剂量帕博利珠单抗的情况下,低剂量方案可能可行且具成本效益。
核心结论
- 在新辅助化疗基础上加用低剂量帕博利珠单抗可统计学显著提高TNBC患者的病理完全缓解率。
- 低剂量方案的获益在数值上与KEYNOTE-522试验所见相似。
研究设计与样本
- II期、开放标签、随机对照研究,在印度新德里一家三级癌症中心开展。
- 纳入既往未治疗的II-III期TNBC患者,且无法获得标准剂量帕博利珠单抗。
- 1:1随机接受剂量密集新辅助化疗(4周期多柔比星-环磷酰胺序贯4周期紫杉醇)联合或不联合低剂量帕博利珠单抗(50 mg每6周共3周期)。
- 主要终点为病理完全缓解。
- 2024年2月至2025年2月共入组157例患者,152例完成手术。
主要发现
- 意向治疗人群中,联合组pCR率为53.8%(90%CI 43.9%-63.5%),对照组为40.5%(90%CI 31.1%-50.4%)。
- 绝对差异为13.3%(90%CI 0.3%-26.3%,单侧P=0.047)。
- 接受手术者中,联合组与对照组pCR率分别为56.7%和41.0%(绝对差异15.7%,单侧P=0.031)。
- 联合组≥3级毒性发生率为50%,对照组为59.5%。
临床怎么用
- 在无法获得标准剂量帕博利珠单抗的环境中,低剂量方案可作为可行且具成本效益的选择。
- 需结合患者分期、毒性风险及药物可及性个体化决策。
局限性
- 为II期开放标签研究,样本量有限。
- 研究在单一中心开展,外部推广性需进一步验证。
- 入组患者为无法获得标准剂量帕博利珠单抗的人群,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Addition of pembrolizumab to neoadjuvant chemotherapy (NACT) is a standard-of-care treatment in non-metastatic triple-negative breast cancer (TNBC). Trials employing reduced doses of immune checkpoint inhibitors have yielded encouraging activity in several tumor types. Whether low-dose pembrolizumab enhances pathological complete response when added to NACT in TNBC remains uncertain. PATIENTS AND METHODS: A phase II, open-label, randomized controlled study was conducted at a tertiary cancer center in New Delhi, India. Eligible participants had previously untreated stage II-III TNBC and lacked access to standard-dose pembrolizumab. Patients were randomly assigned (1 : 1) to receive dose-dense NACT-four cycles of doxorubicin-cyclophosphamide followed by four cycles of paclitaxel with or without a low dose of pembrolizumab (50 mg every 6 weeks for three cycles). The primary endpoint was pathological complete response. RESULTS: Between February 2024 and February 2025, 157 patients were enrolled. Baseline characteristics were comparable between study arms. Surgery was completed in 152 patients. In the intention-to-treat population, pathological complete response was achieved in 53.8% [90% confidence interval (CI) 43.9% to 63.5%] of patients receiving low-dose pembrolizumab + NACT versus 40.5% (90% CI 31.1% to 50.4%) with NACT alone, corresponding to an absolute difference of 13.3% (90% CI 0.3% to 26.3%, one-sided P = 0.047). Among those who underwent surgery, the respective pathological complete response rates were 56.7% and 41.0% (absolute difference 15.7%, one-sided P = 0.031). Grade ≥3 toxicities occurred in 50% of patients in the low-dose pembrolizumab arm and in 59.5% in the control arm. CONCLUSIONS: Addition of low-dose immunotherapy to NACT led to a statistically significant increase in pathological complete response rates, and the benefit appears to be numerically similar to that seen in the KEYNOTE-522 trial. In settings where access to the standard regimen is restricted, a low-dose approach may offer a feasible and cost-effective treatment option for patients with TNBC.
引用
- Arora A, Bhaskarane H, Tansir G, et al. A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC). Ann Oncol. 2025. PMID: 41443410. doi:10.1016/j.annonc.2025.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。